Alivus Life Sciences Q1 FY27 PAT jumps 32% YoY to Rs 1,600.76 mn

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹1115.00

prior close

₹1135.50

announcement price

After-mkt

timing

Nifty Microcap 250market+1.1%+2.2% vs market

Pharmaceuticals peers, median of 164sector+0.1%+3.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-1.1

15m

-1.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3+1.1+2.2+0.1+3.2

Next day

+9.2+2.4+6.8+1.1+8.1

+20.2+2.9+17.3+1.0+19.2

+19.5+4.2+15.3+1.1+18.4

+18.5+4.6+13.9+1.2+17.4

+18.6+4.6+14.0+1.4+17.2

+24.3+4.4+19.9+2.2+22.1

15d

+21.7+5.7+16.0+1.3+20.4

+25.6+6.6+19.0+2.0+23.5

+23.7+5.4+18.3+3.0+20.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences) reported Q1 FY27 revenue from operations of Rs 6,404.14 million, up 6.4% from Rs 6,018.46 million a year ago. Net profit jumped 31.7% YoY to Rs 1,600.76 million versus Rs 1,215.35 million. EPS stood at Rs 13.04 versus Rs 9.91. Total income was Rs 6,628.15 million and profit before tax was Rs 2,122.23 million. Auditor Walker Chandiok gave an unmodified review conclusion.

Likely market impact

Strong profit growth with expanding margins signals improving operational efficiency, positive for shareholders.